IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 306 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,844,560 | +1.4% | 481,582 | -8.3% | 0.08% | +6.9% |
| Q2 2023 | $21,547,479 | +15.7% | 525,164 | +0.8% | 0.07% | +12.5% |
| Q1 2023 | $18,615,822 | -5.5% | 520,868 | -0.1% | 0.06% | -9.9% |
| Q4 2022 | $19,699,699 | +22.1% | 521,570 | +43.0% | 0.07% | +121.9% |
| Q3 2022 | $16,130,606 | +37.4% | 364,712 | +15.0% | 0.03% | +45.5% |
| Q2 2022 | $11,737,966 | +83.6% | 317,070 | +83.7% | 0.02% | +144.4% |
| Q1 2022 | $6,393,552 | +139.0% | 172,600 | +96.4% | 0.01% | +28.6% |
| Q4 2021 | $2,675,000 | +39.5% | 87,900 | +53.7% | 0.01% | +40.0% |
| Q3 2021 | $1,918,000 | -77.9% | 57,200 | -70.3% | 0.01% | -80.8% |
| Q1 2021 | $8,660,000 | -11.6% | 192,629 | +11.1% | 0.03% | -16.1% |
| Q4 2020 | $9,801,000 | +44.5% | 173,347 | +21.3% | 0.03% | +24.0% |
| Q3 2020 | $6,782,000 | +0.5% | 142,925 | +24.9% | 0.02% | +92.3% |
| Q2 2020 | $6,746,000 | -19.7% | 114,422 | -35.6% | 0.01% | -38.1% |
| Q1 2020 | $8,402,000 | -70.2% | 177,688 | -62.0% | 0.02% | -63.2% |
| Q4 2019 | $28,230,000 | -10.8% | 467,292 | -11.5% | 0.06% | -9.5% |
| Q3 2019 | $31,648,000 | -12.9% | 528,244 | -6.5% | 0.06% | -11.3% |
| Q2 2019 | $36,322,000 | +46.8% | 565,156 | +85.4% | 0.07% | -26.8% |
| Q1 2019 | $24,740,000 | +11.2% | 304,787 | -25.9% | 0.10% | 0.0% |
| Q4 2018 | $22,244,000 | +18.2% | 411,475 | +12.8% | 0.10% | +40.6% |
| Q3 2018 | $18,817,000 | +4.0% | 364,820 | -16.0% | 0.07% | 0.0% |
| Q2 2018 | $18,100,000 | +76.5% | 434,355 | +86.7% | 0.07% | +68.3% |
| Q1 2018 | $10,255,000 | +3.0% | 232,635 | +17.6% | 0.04% | +5.1% |
| Q4 2017 | $9,954,000 | +91.3% | 197,898 | +92.9% | 0.04% | +77.3% |
| Q3 2017 | $5,202,000 | -66.0% | 102,604 | -67.9% | 0.02% | -69.4% |
| Q4 2016 | $15,297,000 | +9.2% | 319,819 | -16.4% | 0.07% | +16.1% |
| Q3 2016 | $14,012,000 | +70.6% | 382,415 | +8.5% | 0.06% | +67.6% |
| Q2 2016 | $8,211,000 | -44.8% | 352,549 | -3.9% | 0.04% | -44.8% |
| Q1 2016 | $14,864,000 | -24.3% | 367,016 | +15.8% | 0.07% | -22.1% |
| Q4 2015 | $19,623,000 | – | 316,858 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |